The company plans on initiating a phase 1 clinical trial during the second half of the year, and possibly during the summer. #Vaxart #Phase1 #SecondHalf2020   @themotleyfool #stocks $VXRT $AZN $EBS $KIN $NVAX $MRNA https://t.co/5lhxaBILnB